Perrigo (PRGO) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Perrigo (PRGO) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 26.1% versus a loss of 29.2%. Over five years, PRGO leads with a -57.8% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.21 billion), about 1.0 times the size, while Perrigo is growing revenue faster (-2.8% vs -4.3%).
Perrigo pays a dividend yielding 7.28%, while Arcus Biosciences does not currently pay one. Perrigo converts more of its revenue into profit, with a net margin of -33.5% versus -142.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRGO | RCUS |
|---|---|---|
| Share price | $15.94 | $15.62 |
| Market cap | $2.21B | $2.25B |
| 1-day change | -0.62% | -1.01% |
| YTD return | +14.51% | -34.45% |
| 1-year return | +26.11% | -29.16% |
| 5-year return | -57.81% | -66.31% |
| Forward P/E | 6.94 | — |
| EPS (TTM) | $-12.47 | $-3.64 |
| Dividend yield | 7.28% | 0.00% |
| Annual dividend | $1.16 | $0.00 |
| Revenue (latest FY) | $4.25B | $247.00M |
| Revenue growth (YoY) | -2.75% | -4.26% |
| Net income (latest FY) | $-1.43B | $-353.00M |
| Gross margin | 35.14% | — |
| Operating margin | -26.39% | -156.28% |
| Net margin | -33.51% | -142.91% |
| 52-week high | $17.07 | $31.74 |
| 52-week low | $9.23 | $15.56 |
| Distance from 52-week high | -6.62% | -50.78% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +12.92% | +162.48% |
| Average volume | 2.54M | 1.85M |
| Shares outstanding | 138.80M | 143.99M |
| Employees | 8,100 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRGO has outperformed RCUS by 55.3 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).
- Perrigo is more profitable, keeping -33.5 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
PRGO vs RCUS FAQ
Which is bigger, Perrigo or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.21B for Perrigo (PRGO).
Which stock has performed better over the past year, PRGO or RCUS?
PRGO returned +26.11% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perrigo or Arcus Biosciences?
Perrigo pays a dividend yielding 7.28%, while Arcus Biosciences does not currently pay a regular dividend.
Are Perrigo and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.